BOSTON — October 12, 2026
CervoMed Inc. (NASDAQ: CRVO) announced initial biomarker findings from its Phase 2a clinical trial evaluating neflamapimod in people with nonfluent variant primary progressive aphasia (nfvPPA), a progressive form of frontotemporal dementia (FTD). The open-label study showed an average reduction in plasma neurofilament light chain (NfL) levels during the first 12 weeks of treatment. NfL is a biomarker associated with neuronal injury and degeneration, and the decline was greater in an exploratory subgroup of participants whose baseline NfL levels were at or above the median. The findings were presented in a late-breaking oral session at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia. CervoMed expects to present 24-week biomarker data in November 2026, followed by topline clinical data in the first quarter of 2027.
Neflamapimod Shows Early Changes in Neurodegeneration Biomarker
The initial Phase 2a analysis included 25 participants with nfvPPA. At baseline, 18 participants (72%) had elevated plasma NfL levels relative to the general population, while four participants (16%) had elevated glial fibrillary acidic protein (GFAP) levels. Mean baseline NfL was 45.7 picograms per milliliter (pg/mL), with a standard deviation of 39.6 pg/mL. Mean baseline GFAP was 103.4 pg/mL, with a standard deviation of 43.2 pg/mL. During the first 12 weeks of treatment, mean plasma NfL levels declined by approximately 3.1 pg/mL, with most of the reduction occurring between Weeks 6 and 12. An exploratory analysis of 13 participants whose baseline NfL levels were at or above the median showed a larger mean reduction of approximately 5.7 pg/mL. GFAP levels remained stable over the same period. CervoMed noted that NfL levels are often elevated in nfvPPA and correlate with disease progression. However, these findings represent early biomarker observations from an open-label study and do not yet establish that neflamapimod improves symptoms or slows disease progression.
Phase 2a Trial Evaluates Safety and Treatment Response
The 36-week Phase 2a trial was designed to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod in people with nfvPPA. Conducted at academic medical centers in the United States and United Kingdom, the study enrolled 25 participants and includes an initial 24-week open-label treatment period followed by a 12-week randomized withdrawal phase. During the open-label period, 19 participants received neflamapimod at 40 mg three times daily, while six received 80 mg twice daily. In the subsequent double-blind, placebo-controlled withdrawal period, participants are assigned in a 1:1 ratio either to continue treatment or switch to placebo. The investigational drug was generally well tolerated during the reported period, and the company identified no new safety signals. One participant developed elevated liver enzyme levels that met the protocol-defined criteria for discontinuation. The participant was asymptomatic, had no associated bilirubin elevation, and the enzyme elevation resolved after treatment was discontinued. Further data will be needed to characterize the candidate’s safety profile and determine whether the observed biomarker changes are accompanied by meaningful clinical benefits.
Advertisement
Neflamapimod Targets Neuroinflammation and Synaptic Dysfunction
Neflamapimod is an investigational oral small-molecule drug that crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 mitogen-activated protein kinase, or p38α MAP kinase. This enzyme is involved in pathways associated with neuroinflammation and synaptic dysfunction. Preclinical research has linked p38α activity to neuronal deficits associated with tau pathology, providing a scientific rationale for studying neflamapimod in nfvPPA. The condition progressively affects a person’s ability to produce speech, including forming sentences and pronouncing words, and can eventually impair communication and everyday functioning. Tau pathology is commonly associated with this form of frontotemporal dementia, although the underlying pathology can vary among individuals. There are currently no approved pharmacological treatments for nfvPPA in the United States or European Union, highlighting the unmet medical need. Neflamapimod is also being investigated in dementia with Lewy bodies, recovery following ischemic stroke and amyotrophic lateral sclerosis. The drug has received U.S. Food and Drug Administration Fast Track designation for dementia with Lewy bodies and Orphan Drug designation for nfvPPA.
Source::CervoMed,, press release
